tetano
Editor, Senior Moderator
Clin J Gastroenterol
. 2021 Mar 6.
doi: 10.1007/s12328-021-01374-x. Online ahead of print.
The case of a liver-transplant recipient with severe acute respiratory syndrome coronavirus 2 infection who had a favorable outcome
Kazuhiko Hayashi[SUP] 1 [/SUP], Yuki Ito[SUP] 2 [/SUP], Ryosuke Yamane[SUP] 2 [/SUP], Michiyo Yoshizaki[SUP] 2 [/SUP], Komei Matsushita[SUP] 2 [/SUP], Go Kajikawa[SUP] 2 [/SUP], Takashi Kozawa[SUP] 2 [/SUP], Taro Mizutani[SUP] 2 [/SUP], Yuko Shimizu[SUP] 2 [/SUP], Kenichi Nagano[SUP] 2 [/SUP], Kosuke Tachi[SUP] 2 [/SUP], Kentaro Yoshioka[SUP] 2 [/SUP], Hidemi Goto[SUP] 2 [/SUP]
Affiliations
Abstract
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in 2019; thereafter, the COVID-19 outbreak became a health emergency of international concern. The impact of COVID-19 on liver-transplant recipients is unclear. Thus, it is currently unknown whether liver-transplant recipients are at a higher risk of developing complications related to COVID-19. Here, we report the case of liver-transplant recipients who were infected with SARS-CoV-2. A 20-year-old man who had undergone living-donor liver transplantation from his father at 5 years of age because of congenital biliary atresia was referred to our hospital for SARS-CoV-2 infection. Chest computed tomography did not show any abnormalities; however, laboratory results revealed liver dysfunction. He received tacrolimus as maintenance therapy that was continued at the same dose. He has not developed severe pulmonary disease and was discharged after 10 days of hospitalization. Limited data are available on post-transplant patients with COVID-19, and this case of a young patient without metabolic comorbidities did not show any association of severe COVID-19 under tacrolimus treatment. The progression of COVID-19 in liver-transplant recipients is complex, and COVID-19 risk should be evaluated in each patient until the establishment of optimal guidelines.
Keywords: Coronavirus disease 2019; Liver transplantation; Severe acute respiratory syndrome coronavirus 2.
. 2021 Mar 6.
doi: 10.1007/s12328-021-01374-x. Online ahead of print.
The case of a liver-transplant recipient with severe acute respiratory syndrome coronavirus 2 infection who had a favorable outcome
Kazuhiko Hayashi[SUP] 1 [/SUP], Yuki Ito[SUP] 2 [/SUP], Ryosuke Yamane[SUP] 2 [/SUP], Michiyo Yoshizaki[SUP] 2 [/SUP], Komei Matsushita[SUP] 2 [/SUP], Go Kajikawa[SUP] 2 [/SUP], Takashi Kozawa[SUP] 2 [/SUP], Taro Mizutani[SUP] 2 [/SUP], Yuko Shimizu[SUP] 2 [/SUP], Kenichi Nagano[SUP] 2 [/SUP], Kosuke Tachi[SUP] 2 [/SUP], Kentaro Yoshioka[SUP] 2 [/SUP], Hidemi Goto[SUP] 2 [/SUP]
Affiliations
- PMID: 33675512
- DOI: 10.1007/s12328-021-01374-x
Abstract
The outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in 2019; thereafter, the COVID-19 outbreak became a health emergency of international concern. The impact of COVID-19 on liver-transplant recipients is unclear. Thus, it is currently unknown whether liver-transplant recipients are at a higher risk of developing complications related to COVID-19. Here, we report the case of liver-transplant recipients who were infected with SARS-CoV-2. A 20-year-old man who had undergone living-donor liver transplantation from his father at 5 years of age because of congenital biliary atresia was referred to our hospital for SARS-CoV-2 infection. Chest computed tomography did not show any abnormalities; however, laboratory results revealed liver dysfunction. He received tacrolimus as maintenance therapy that was continued at the same dose. He has not developed severe pulmonary disease and was discharged after 10 days of hospitalization. Limited data are available on post-transplant patients with COVID-19, and this case of a young patient without metabolic comorbidities did not show any association of severe COVID-19 under tacrolimus treatment. The progression of COVID-19 in liver-transplant recipients is complex, and COVID-19 risk should be evaluated in each patient until the establishment of optimal guidelines.
Keywords: Coronavirus disease 2019; Liver transplantation; Severe acute respiratory syndrome coronavirus 2.